Besides its essential role in hemostasis, there is growing evidence that von Willebrand factor (VWF) has an additional antitumor effect. To elucidate the clinical significance of this biological activity we conducted a retrospective study on cancers among Italian patients with von Willebrand disease (VWD) on behalf of the Italian Association of Haemophilia Centres (AICE). A questionnaire to collect demographic, clinical, and treatment data of VWD patients with cancer was sent to all the 54 Italian Haemophilia Treatment Centres (HTCs) members of AICE. Overall, 18 HTCs (33%) provided information on 92 VWD patients (61 alive and 31 deceased) with 106 cancers collected during the period 1981 to 2014. Of them, 19 (18%) were hematological cancers and 87 (82%) were solid cancers. A total of 61% of patients had type 1, 36% type 2 (12% type 2A, 14% type 2B, 9% type 2M, and 1% type 2N), and 3% type 3 VWD: this distribution was significantly different from that observed in the whole VWD population (79% type 1, 16% type 2 [8% type 2A, 4% type 2B, 2% type 2M, 2% type 2N], and 5% type 3; type 2 vs. non-type 2: p < 0.001). Overall, VWD patients with cancer underwent 52 invasive and 72 surgical procedures, were treated with VWF/factor VIII (FVIII) concentrates in 77 cases, with desmopressin (DDAVP) alone in 24 cases and with DDAVP and VWF/FVIII Ã The complete list of coauthors for the study (Italian Association of Haemophilia Centres, with the site of the Haemophilia Centre given in parentheses, is as follows.
von Willebrand factor (VWF), a large multimeric plasma protein synthesized by endothelial cells and megakaryocytes, plays a key role in promoting platelet adhesion and aggregation and in protecting coagulation factor VIII (FVIII) from proteolytic degradation. [1] [2] [3] Besides its essential role in hemostasis, there is an increasing evidence that VWF may have an additional antitumor effect, mainly through its antiangiogenic and proapoptotic properties. 4 Indeed, while the antiangiogenic action is exerted mostly by a negative modulation of vascular endothelial growth factor receptor-2-dependent angiogenesis, 5 some experimental in vitro and in vivo studies have demonstrated a critical role of VWF in reducing metastasis by inducing tumor cell death. 6, 7 With this background, it is not surprising that several clinical studies have analyzed the relationship between circulating or tissue VWF levels and malignancies, [8] [9] [10] [11] [12] [13] [14] [15] but the interpretation of their results is greatly hindered by the fact that VWF levels may be altered during inflammation. It is, therefore, often difficult to establish exactly whether raised VWF levels are causal or a consequence of the underlying cancer-associated inflammatory process. On the other hand, so far only few studies, published exclusively as case reports, [16] [17] [18] have systematically analyzed the issue of cancer in patients with congenital von Willebrand disease (VWD). Thus, on behalf of the Italian Association of Haemophilia Centres (AICE), we have conducted a study on cancer among Italian VWD patients followed at the Haemophilia Treatment Centres (HTCs) with the aim of shedding light on this still unclear issue.
Patients and Methods

Study Design
This retrospective study was approved by the Institutional Review Boards of AICE and by local ethical committees of the hospitals of the participating HTCs and was proposed at the beginning of 2012 to all member HTCs. The primary objective of the study was to describe the cases of cancer (type of neoplasm, patients' outcome, and type of treatment used) in the Italian population of VWD patients. A secondary aim was to investigate the influence, if any, of this inherited hemorrhagic disorder on the management and outcome of malignancies. Another secondary objective of our study was to assess whether a correlation exists between the entity of the VWF defect and the dissemination of malignancy at presentation. A questionnaire designed to collect information on demographic, clinical, and therapeutic data of VWD patients with cancer was sent to all Italian HTCs that are members of AICE. All cases of confirmed cancer in VWD patients, alive or deceased and followed by the HTCs participating in the survey, were included. No restriction of period of inclusion was required. For each case, the following information was recorded: demographic data (date of birth, age at death, and cause of death), type and severity of VWD, VWF ristocetin cofactor (VWF:RCo) levels, type of mutation (if known), presence of blood-borne viral infections and their complications (i.e., chronic hepatitis B, chronic hepatitis C, liver cirrhosis, hepatocellular carcinoma, human immunodeficiency virus [HIV] and acquired immunodeficiency syndrome, response to antiviral treatment for hepatitis C virus [HCV] or HIV), concomitant diseases, and therapeutic data (type of VWF/FVIII concentrate, desmopressin [DDAVP, Kedrion Biopharma, Castelvecchio Pascoli, Italy] usage, treatment regimen, and mean annual consumption). In addition, information was also collected on the type and stage of cancer, the date of diagnosis, the date and type of metastases, data on malignancy management (invasive/surgical procedures, factordeficient replacement therapy and bleeding complications at presentation and during treatment, type of chemotherapy or radiotherapy), occurrence of thrombocytopenia (platelet count < 50 Â 10 9 /L), response to treatment, cancer progression or recurrence, outcome (alive or deceased) and the period of follow-up. All patients had regular followup visits at the HTC. We also collected information on whether VWD had influenced the choice and availability of cancer treatment modalities, patients' participation in experimental protocols, and completion of therapy or whether a reduction of the doses of chemotherapy had been necessary.
Statistical Analysis
All patients enrolled in the study were included in the descriptive statistical analysis. Descriptive analyses of the data were performed using summary statistics for categorical and quantitative data. The null hypothesis of a uniform distribution of the frequencies between different groups was analyzed by means of a Pearson chi-square test. Additionally, multivariable logistic analysis was performed and results are presented as odds ratios (OR) and corresponding 95% confidence intervals (CI).
Results
Total 18 of the 54 (33%) Italian HTCs that are members of AICE agreed to participate in the study and provided concentrates in 7 cases. Hemorrhagic complications were observed only rarely (2% of invasive procedures and radiotherapy and 6% of surgical interventions). The data collected by this survey document that a substantial number of cancers are recorded among VWD patients and that these patients are safely managed by HTC physicians through a multidisciplinary approach. . 32 In this study, 83% of patients were infected by HCV and 22% of them were also coinfected by HIV. A total of 43% of cancers were HCV-related, while 9% were HIV-related. Virus-related cancers were more frequent and nonvirus-related cancers less frequent in patients with severe hemophilia than in those with mild/moderate forms (p ¼ 0.0004). Notably, considering nonvirus-related cancers, a low standardized mortality ratio (0.3) was found. Hemorrhagic complications occurred more frequently in patients undergoing chemotherapy (14%) or radiotherapy (19%). We therefore decided to do the same survey in Italian VWD patients. To our knowledge, this is the first study systematically investigating the occurrence of cancers in a cohort of VWD patients. This issue is however, in our opinion, potentially of great interest, also considering the implication of VWF in angiogenesis and tumor growth processes. Although we could not perform an epidemiological analysis of our data due to the limited number of cancer cases collected, some interesting information did emerge from this study. First of all, the lower number of VWD cancer patients infected by HCV and HIV infection (15% and 2%, respectively) as compared with hemophilia patients reported in our previous survey 32 reflects on the one hand the generally lesser clinical severity of VWD (with consequently less need for replacement therapy) and on the other hand the widespread use of DDAVP which prevented the exposure of a large number of VWD patients to nonvirally inactivated VWF/FVIII concentrates which were responsible for the transmission of blood-borne viruses during the 1970s and the first half of the 1980s. 33 The results of our study further support the association between HCV and cancers: indeed, all cases of hepatocellular carcinoma occurred in HCV-infected VWD patients and approximately 30% of the cases of non-Hodgkin lymphoma were recorded in patients with concomitant HCV infection, in keeping with current literature data. 34 The most striking finding of our study was, however, the association between VWD type and cancer. Indeed, we found an inversion of the ratio among the various VWD types, VWD type 2 being significantly more frequent in our cohort of cancer VWD patients than in the whole VWD population followed at the 18 HTCs participating in the study (33/92 [36%] vs. 236/1465 [16%]). This finding is particularly intriguing considering that, of the various different VWD types, VWD type 2 (especially subtype 2A) is that most frequently associated with angiodysplasia and thus could be involved in the abnormal angiogenesis at the basis of tumorigenesis. 35, 36 The hypothesis that cancer occurrence in VWD patients might be related to a qualitative rather than a quantitative VWF defect is further strengthened by the fact that the median basal VWF levels did not differ significantly between VWD patients with or without a more aggressive malignancy (i.e., with metastasis) at presentation. Notably, the fact that 80% of hemorrhagic complications associated with invasive or surgical procedures occurred in patients not receiving hemostatic treatment underlines the importance of prophylactic antihemorrhagic therapy, also in patients with milder VWD forms. Interestingly, although hemorrhagic complications occurred only rarely, 29% (2/7) of such complications were observed in VWD cancer patients undergoing radiotherapy, probably reflecting a synergistic effect between treatment-related mucosal damage and the VWDassociated tendency to mucosal bleeding. This finding suggests that particular caution should be taken and antihemorrhagic prophylaxis should be considered before starting radiotherapy in such patients at increased risk of mucosal bleeding. Finally, the finding that none of the cases of cancer metastasis at diagnosis occurred in patients with VWD type 3 is potentially interesting but needs to be confirmed by larger studies.
In conclusion, the data collected by this survey document that a substantial number of cancers are recorded among VWD patients and that they can usually be managed safely by physicians operating at HTCs through a multidisciplinary approach. Further experimental and clinical studies are needed to assess whether or not VWD predisposes to cancer. 
